Egypt - English - EDA (Egyptian Drug Authority)

glaxo smithkline-egypt - injection - 15 mcg/0.5ml

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline phils inc - influenza vaccine (split virion, inactivated) northern hemisphere 2013-2014 strain - suspension for injection im/sc - 15mcg / 0.5ml

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: glaxosmithkline philippines, inc.; distributor: glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2023 strain - suspension for injection (im) - formulation: each dose (0.5 ml) contains:* a/sydney/5/2021 (h1n1)pdm09-like strain 15 μg ha** (a/sydney/5/2021, ivr-229) a/darwin/9/2021 (h3n2)-like strain 15 μg ha** (a/darwin/6/2021, ivr-227) b/austria/1359417/2021-like strain 15 μg ha** (b/austria/1359417/2021, bvr-26) [victoria lineage] b/phuket/3073/2013-like strain 15 μg ha** (b/phuket/3073/2013, wild type) [yamagata lineage] *propagated in embryonated eggs **haemagglutinin

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - quadrivalent seasonal influenza vaccine (split virion, inactivated) northern hemisphere 2016/2017 strain (see formulation on reverse side) - suspension for injection (i.m.) - refer to generic name

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - seasonal influenza vaccine (split virion, inactivated) southern hemisphere 2016 (see formulation on reverse side) - suspension for injection (im/sc) - refer to generic name

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

glaxosmithkline biologicals. - b/phuket/3073/2013 - like strain b/phuket/3073/2013, wild type [yamagata lineage] - b/phuket/3073/2013 - like strain b/phuket/3073/2013, wild type [yamagata lineage]....15 µg ha* / a/sydney/5/2021 (h1n1) pdm09 – like strain (asydney/5/2021 , ivr- 229)....15 µg ha* / a/darwin/9/2021 (h3n2) - like strain – (a/darwin/6/2021, ivr-227)....15 µg ha*

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

glaxosmithkline (gsk) - influenza vaccine - solution for injection - 0.5 ml

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

glaxosmithkline south africa (pty) limited - injection - see ingredients - each 0,5 ml dose contains : influenza virus a influenza virus vaccine a

Namibia - English - Namibia Medicines Regulatory Council

glaxosmithkline s.a (pty) ltd - combination - liquid - each 0.5ml dose contains: a/new caledonia /20/99 (ivr-116)(h1h1-line strain 15?g haemagglutinin, a/panama/2007/99 (resvir-17) fo

United States - English - NLM (National Library of Medicine)

protein sciences corporation - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen (unii: 69h0yj871t) (influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen - unii:69h0yj871t), influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen (unii: 2i1eol437m) (influenza a virus a/hong kong/4801/2014 (h3n2) recombinant hemagglutinin antigen - unii:2i1eol437m), influenza b virus b/brisbane/60/2008 recombinant hemagglutinin antigen (unii: 058u2312cr) (influenza b virus b/bri - influenza a virus a/michigan/45/2015 (h1n1) recombinant hemagglutinin antigen 45 ug in 0.5 ml - flublok is a vaccine indicated for active immunization against disease caused by influenza a virus subtypes and influenza type b virus contained in the vaccine. flublok is approved for use in persons 18 years of age and older. flublok is contraindicated in individuals with known severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine (see postmarketing experience [6.2] and description [11] ). pregnancy outcomes in women who have been exposed to flublok during pregnancy are being monitored. contact: protein sciences corporation by calling 1-888-855-7871. all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2% to 4% and 15% to 20%, respectively. available data on flublok administered to pregnant women are insufficient to inform vaccine-associated risks in pregnant women. a developmental study of flublok has been performed in